Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials

• URL: http://arxiv.org/abs/2004.13611v1
• Date: Tue, 28 Apr 2020 15:44:41 GMT
• Title: Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials
• Abstract summary: Increased patient heterogeneity can weaken the ability of common statistical approaches to detect treatment differences. A list of baseline covariates that have the potential to be prognostic for survival under either treatment is pre-specified. A conditional inference tree algorithm is used to segment the heterogeneous trial population into subpopulations of prognostically homogeneous patients. The impressive power-boosting performance of our proposed 5-step stratified testing and amalgamation routine (5-STAR) is illustrated.
• Score: 0.0
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Randomized clinical trials are often designed to assess whether a test treatment prolongs survival relative to a control treatment. Increased patient heterogeneity, while desirable for generalizability of results, can weaken the ability of common statistical approaches to detect treatment differences, potentially hampering the regulatory approval of safe and efficacious therapies. A novel solution to this problem is proposed. A list of baseline covariates that have the potential to be prognostic for survival under either treatment is pre-specified in the analysis plan. At the analysis stage, using all observed survival times but blinded to patient-level treatment assignment, 'noise' covariates are removed with elastic net Cox regression. The shortened covariate list is used by a conditional inference tree algorithm to segment the heterogeneous trial population into subpopulations of prognostically homogeneous patients (risk strata). After patient-level treatment unblinding, a treatment comparison is done within each formed risk stratum and stratum-level results are combined for overall statistical inference. The impressive power-boosting performance of our proposed 5-step stratified testing and amalgamation routine (5-STAR), relative to that of the logrank test and other common approaches that do not leverage inherently structured patient heterogeneity, is illustrated using a hypothetical and two real datasets along with simulation results. Furthermore, the importance of reporting stratum-level comparative treatment effects (time ratios from accelerated failure time model fits in conjunction with model averaging and, as needed, hazard ratios from Cox proportional hazard model fits) is highlighted as a potential enabler of personalized medicine. A fiveSTAR R package is available at https://github.com/rmarceauwest/fiveSTAR.

Related papers

• Surv-IPTB: An Attention-Based Model for Estimating Individual Probability of Treatment Benefit with Survival Data [0.6882042556551609]
  The proposed model, called Surv-IPTB, directly quantifies the probability that a specific patient will experience extended survival time under treatment versus control.<n>We reformulate IPTB estimation as a binary classification problem, leveraging pairwise patient comparisons across treatment and control cohorts.<n>An attention mechanism with learnable query-key transformations enables flexible, data-driven aggregation of pairwise comparisons.
  arXiv  Detail & Related papers  (2026-08-06T17:13:44Z)
• A Guide to Estimating Conditional Average Treatment Effects in Competing Risks Settings [1.7900262205172117]
  Conditional average treatment effects (CATEs) are central to treatment decision-making in personalized medicine.<n>In competing risks settings, estimating CATEs from survival data allows for patient-specific assessments of treatment effectiveness.<n>We study meta-learners which adapt machine learning algorithms for CATE estimation in competing risks scenarios.
  arXiv  Detail & Related papers  (2026-06-08T15:58:08Z)
• Estimating heterogeneous treatment effects with survival outcomes via a deep survival learner [5.540352966241158]
  Estimating heterogeneous treatment effects in survival settings is complicated by right censoring and the time-varying nature of the estimand.<n>We propose a deep survival learner for estimating heterogeneous treatment effects with right-censored outcomes.
  arXiv  Detail & Related papers  (2026-04-12T01:11:44Z)
• PRIME: Prototype-Driven Multimodal Pretraining for Cancer Prognosis with Missing Modalities [86.63247982275396]
  PRIME is a missing-aware multimodal self-supervised pretraining framework.<n>It learns robust and transferable representations from partially observed cohorts.<n>We evaluate PRIME on The Cancer Genome Atlas with label-free pretraining on 32 cancer types.
  arXiv  Detail & Related papers  (2026-04-05T21:14:27Z)
• Deep Variational Contrastive Learning for Joint Risk Stratification and Time-to-Event Estimation [9.592144785458443]
  CONVERSE is a deep survival model that unifies variational autoencoders with contrastive learning for interpretable risk stratification.<n>It achieves competitive or superior performance compared to existing deep survival methods, while maintaining meaningful patient stratification.
  arXiv  Detail & Related papers  (2026-02-01T18:07:40Z)
• An Interpretable AI Tool for SAVR vs TAVR in Low to Intermediate Risk Patients with Severe Aortic Stenosis [3.1857591443934816]
  We introduce an interpretable prescriptive framework that integrates prognostic matching, counterfactual outcome modeling, and an Optimal Policy Tree (OPT)<n>If the OPT prescriptions are applied, counterfactual evaluation showed an estimated reduction in 5-year mortality of 20.3% in Hartford and 13.8% in St. Vincent's relative to real-life prescriptions.
  arXiv  Detail & Related papers  (2025-12-11T05:54:22Z)
• Robust estimation of heterogeneous treatment effects in randomized trials leveraging external data [1.3124513975412255]
  We propose the QR-learner, a model-agnostic learner that estimates conditional average treatment effects (CATE) within the trial population.<n>It has the potential to reduce the CATE prediction mean squared error while maintaining consistency, even when the external data is not aligned with the trial.<n>We apply the methods to a real-world dataset, demonstrating improvements in both CATE estimation and statistical power for detecting heterogeneous effects.
  arXiv  Detail & Related papers  (2025-07-04T16:01:05Z)
• Comparison of the Cox proportional hazards model and Random Survival Forest algorithm for predicting patient-specific survival probabilities in clinical trial data [0.0]
  Cox proportional hazards model is often used to analyze data from Randomized Controlled Trials (RCT) with time-to-event outcomes.<n> Random survival forest (RSF) is a machine-learning algorithm known for its high predictive performance.<n>We compare the performance of Cox regression and RSF in various simulation scenarios based on two reference from RCTs.
  arXiv  Detail & Related papers  (2025-02-05T12:26:43Z)
• SeqRisk: Transformer-augmented latent variable model for improved survival prediction with longitudinal data [4.1476925904032464]
  We propose SeqRisk, a method that combines variational autoencoder (VAE) or longitudinal VAE (LVAE) with a transformer encoder and Cox proportional hazards module for risk prediction. We demonstrate that SeqRisk performs competitively compared to existing approaches on both simulated and real-world datasets.
  arXiv  Detail & Related papers  (2024-09-19T12:35:25Z)
• Estimating treatment effects from single-arm trials via latent-variable modeling [14.083487062917085]
  Single-arm trials, where all patients belong to the treatment group, can be a viable alternative but require access to an external control group. We propose an identifiable deep latent-variable model for this scenario. Our results show improved performance both for direct treatment effect estimation as well as for effect estimation via patient matching.
  arXiv  Detail & Related papers  (2023-11-06T10:12:54Z)
• Robust and Agnostic Learning of Conditional Distributional Treatment Effects [62.44901952244514]
  The conditional average treatment effect (CATE) is the best point prediction of individual causal effects. In aggregate analyses, this is usually addressed by measuring distributional treatment effect (DTE) We provide a new robust and model-agnostic methodology for learning the conditional DTE (CDTE) for a wide class of problems.
  arXiv  Detail & Related papers  (2022-05-23T17:40:31Z)
• Treatment Effect Risk: Bounds and Inference [58.442274475425144]
  Since the average treatment effect measures the change in social welfare, even if positive, there is a risk of negative effect on, say, some 10% of the population. In this paper we consider how to nonetheless assess this important risk measure, formalized as the conditional value at risk (CVaR) of the ITE distribution. Some bounds can also be interpreted as summarizing a complex CATE function into a single metric and are of interest independently of being a bound.
  arXiv  Detail & Related papers  (2022-01-15T17:21:26Z)
• CDSM -- Casual Inference using Deep Bayesian Dynamic Survival Models [3.9169188005935927]
  We have developed a causal dynamic survival model (CDSM) that uses the potential outcomes framework with the Bayesian recurrent sub-networks to estimate the difference in survival curves. Using simulated survival datasets, CDSM has shown good causal effect estimation performance across scenarios of sample dimension, event rate, confounding and overlapping.
  arXiv  Detail & Related papers  (2021-01-26T09:15:49Z)
• Bayesian prognostic covariate adjustment [59.75318183140857]
  Historical data about disease outcomes can be integrated into the analysis of clinical trials in many ways. We build on existing literature that uses prognostic scores from a predictive model to increase the efficiency of treatment effect estimates.
  arXiv  Detail & Related papers  (2020-12-24T05:19:03Z)
• Increasing the efficiency of randomized trial estimates via linear adjustment for a prognostic score [59.75318183140857]
  Estimating causal effects from randomized experiments is central to clinical research. Most methods for historical borrowing achieve reductions in variance by sacrificing strict type-I error rate control.
  arXiv  Detail & Related papers  (2020-12-17T21:10:10Z)
• A standardized framework for risk-based assessment of treatment effect heterogeneity in observational healthcare databases [60.07352590494571]
  The aim of this study was to extend this approach to the observational setting using a standardized scalable framework. We demonstrate our framework by evaluating the effect of angiotensin-converting enzyme (ACE) inhibitors versus beta blockers on three efficacy and six safety outcomes.
  arXiv  Detail & Related papers  (2020-10-13T14:48:31Z)
• Estimating heterogeneous survival treatment effect in observational data using machine learning [9.951103976634407]
  Methods for estimating heterogeneous treatment effect in observational data have largely focused on continuous or binary outcomes. Using flexible machine learning methods in the counterfactual framework is a promising approach to address challenges due to complex individual characteristics.
  arXiv  Detail & Related papers  (2020-08-17T01:02:14Z)
• Enabling Counterfactual Survival Analysis with Balanced Representations [64.17342727357618]
  Survival data are frequently encountered across diverse medical applications, i.e., drug development, risk profiling, and clinical trials. We propose a theoretically grounded unified framework for counterfactual inference applicable to survival outcomes.
  arXiv  Detail & Related papers  (2020-06-14T01:15:00Z)
• Joint Prediction and Time Estimation of COVID-19 Developing Severe Symptoms using Chest CT Scan [49.209225484926634]
  We propose a joint classification and regression method to determine whether the patient would develop severe symptoms in the later time. To do this, the proposed method takes into account 1) the weight for each sample to reduce the outliers' influence and explore the problem of imbalance classification. Our proposed method yields 76.97% of accuracy for predicting the severe cases, 0.524 of the correlation coefficient, and 0.55 days difference for the converted time.
  arXiv  Detail & Related papers  (2020-05-07T12:16:37Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.